
ART.1 is available for clinical use in the United Kingdom, the European Union and Australia. FDA 510(k) pending.
Founded by Dr Trang Nguyen and Prof Paul Keall in 2023, SeeTreat is led by award-winning researchers, engineers, and clinicians with a combined experience in radiation oncology of over 300 years.
Transforming treatment without hardware barriers
We develop software solutions that enhance patient care and clinical efficiency without requiring hardware upgrades.
People-first innovation
At the heart of SeeTreat is a passion for solving real-world problems in cancer treatment. We are committed to improving the experiences of both patients and clinicians. Our workplace culture is built on innovation, collaboration, and inclusivity, where diverse perspectives are valued, and bold ideas are encouraged.


ART.1 analyzes every structure, allowing configurable, personalized protocols to analyze any structure with any metric.
Your department workflow, your protocols, your results.

ART.1’s fraction-by-fraction deviation analysis provides a history of results, boosting confidence in replan decisions.
Your patient’s treatment story is unique.

ART.1 automatically evaluates all patients in the background, prioritizing those who need attention the most, allowing for adaptive decision-making in minutes.
Automatic robust image registration and dose calculation built in.
Trend plots and traffic-light alerts surface only the patients who need attention.
Complete automation and integration with major vendors
Objective decision support, replan at your pace.

“ART.1 changes what's possible in adaptive radiotherapy. It gives clinicians continuous visibility into how treatment is evolving for each patient, bridging the gap between planning and real-world delivery in a way that's been missing until now”
Prof. Jarad MartinPracticing radiation oncologist (MBChB BSc PhD DMed FRANZCR GAustMS)